News
ATHXQ
0.0045
+36.36%
0.0012
Weekly Report: what happened at ATHXQ last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at ATHXQ last week (0401-0405)?
Weekly Report · 04/08 10:33
Athersys Finalizes Sale to HEALIOS Amidst Board Reorganization
TipRanks · 04/05 20:32
Weekly Report: what happened at ATHXQ last week (0325-0329)?
Weekly Report · 04/01 10:32
Weekly Report: what happened at ATHXQ last week (0318-0322)?
Weekly Report · 03/25 10:35
Weekly Report: what happened at ATHXQ last week (0311-0315)?
Weekly Report · 03/18 10:33
Biotech bankruptcies hit a record despite sector’s recovery
Healthcare Biotech bankruptcies hit a record despite sector’s recovery. More biotech firms filed for Chapter 11 bankruptcy than any other year since 2010. In 2023, 18 biotech companies petitioned for court-mediated protection, compared to eight in 2022. The record number of biotech bankruptcies contrasts with the industry's recent gains.
Seeking Alpha · 03/14 18:54
Weekly Report: what happened at ATHXQ last week (0304-0308)?
Weekly Report · 03/11 10:31
Weekly Report: what happened at ATHXQ last week (0226-0301)?
Weekly Report · 03/04 10:33
Weekly Report: what happened at ATHXQ last week (0219-0223)?
Weekly Report · 02/26 10:42
Weekly Report: what happened at ATHXQ last week (0212-0216)?
Weekly Report · 02/19 10:43
Weekly Report: what happened at ATHXQ last week (0205-0209)?
Weekly Report · 02/12 10:36
Weekly Report: what happened at ATHXQ last week (0129-0202)?
Weekly Report · 02/05 10:42
Weekly Report: what happened at ATHXQ last week (0122-0126)?
Weekly Report · 01/29 10:34
Weekly Report: what happened at ATHXQ last week (0115-0119)?
Weekly Report · 01/22 10:37
Weekly Report: what happened at ATHXQ last week (0108-0112)?
Weekly Report · 01/15 10:35
Athersys to Sell Most Assets to Healios
Athersys will sell virtually all of its assets to regenerative medicine and cell therapy company Healios in an agreement valued at $2 million. Athersys said it will receive $2million in the form of a credit bid. The clinical-stage biotechnology company filed for bankruptcy on Friday.
Dow Jones · 01/08 13:11
*Athersys Says It Entered Into Stalking Horse Asset Purchase Agreement with Healios K.K. >ATHX
Dow Jones · 01/08 12:45
*Athersys, Units File Motion Seeking Approval of Certain Sale, Bid, Auction Procedures to Sell Substantially All Assets to Stalking Horse Bidder >ATHX
Dow Jones · 01/08 12:42
*Athersys and Subsidiaries Filed for Relief under Chapter 11 of U.S. Bankruptcy Code >ATHX
Dow Jones · 01/08 12:38
More
Webull provides a variety of real-time ATHXQ stock news. You can receive the latest news about Athersys Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATHXQ
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).